The global deep brain stimulation devices market size was USD 1.15 Billion in 2021 and is expected to register a revenue CAGR of 10.2% during the forecast period. Increasing incidence rate of neurological disorders globally is a key factor expected to drive market revenue growth to a significant extent over the forecast period. Rising prevalence of neurological disorders is increasing the need and demand for required devices and equipment for respective treatment procedures. Rising focus on developing thin film electrodes to reduce the rate of invasiveness, patient discomfort, risk of infections, and post-operative complications is another factor driving revenue growth of the market. For instance, NeuroOne Medical Technologies Corp., which is a next-generation electrode technology company, is developing thin-film electrode that is minimally invasive in nature for diagnosing and treating various neurological disorders such as epilepsy, essential tumor, and Parkinson’s Disease. In addition, increasing preference for minimally invasive surgical procedures and treatments has been contributing to increasing implementation of Deep Brain Stimulation (DBS) procedure in the treatment of neurological disorders, which is expected to contribute significantly to revenue growth of the global deep brain stimulation devices market going ahead.
Deep brain stimulation is a neurosurgical procedure that enables targeted circuit-based neuromodulation in the brain. The procedure involves implantation of a medical device called a neurostimulator to deliver electrical impulses to the targeted areas of the brain to regulate abnormal brain activity and chemical imbalances within the brain which cause a variety of neurological conditions. DBS is an established therapeutic modality for treatment of movement disorders such as dystonia Parkinson’s Disease, essential tumor, and neuropsychiatric disorder such as Obsessive Compulsory Disorder (OCD) and it is currently under active investigation for a number of other conditions associated with pathological circuitry such as Alzheimer’s Disease and major depressive disorder. DBS is showing promising results for various neurological disorders such as epilepsy and Tourette Syndrome (TS), which are refractory to traditional therapy.
Request a Sample@ https://www.qyresearchmedical.com/sample/119140
Rising competition in deep brain stimulation hardware industry is leading to the development of multiple DBS systems with different leads, batteries, and extensions, which are approved by both U.S. and European regulatory agencies. Rapid advancements in functioning and structural imaging technologies are providing ample number of new brain targets for a growing number of pathologies, which is leading to investigations of DBS in numerous cognitive, behavioral, psychiatric, and neurological conditions. Rapid technological advancements are also resulting in development and launch of pulse generators with longer battery life, segmental electrode enabling current steering, and development of on-demand closed loop deep brain stimulation system. However, high risk of post-operative complications after DBS procedure and high cost of the procedure are key factors expected to hamper growth of the deep brain stimulation devices market to a certain extent during forecast period.
Driver: Rising incidence rate of neurological disorders
Rising incidence rate of neurological disorders such as Parkinson’s Diseases, dystonia, and essential tumor across the globe is driving revenue growth of the market. Increasing global geriatric population is contributing to rise in number of neurodegenerative diseases, and in recent years, DBS has been proving effective for reducing motor symptoms associated with Parkinson’s Disease, epilepsy, dystonia, and essential tumor. The therapeutic success of DBS has been prompting scientists and researchers to apply the procedure for an increasing spectrum of neurological conditions such as Tourette Syndrome, traumatic brain injury, dementia, and chronic pain, among others. Deep brain stimulation is a promising treatment modality for refractory disorders such as OCD and major depression, which is expected to boost revenue growth of the market over the forecast period.
Restraint: High risk of post-operative complications after DBS procedure
Deep brain stimulation can sometimes lead to mild or serious complications post-operation. Some include infections, gait problems, or paralysis. High surgical risks is expected to be higher in elderly individuals or persons suffering from co-morbidities such as high blood pressure or cerebrovascular diseases. During the procedure, microelectrodes are inserted on the brain to deliver electric signal or impulses to the targeted area, which sometimes can cause puncturing of blood vessels, thereby causing stroke or stroke-related syndrome. This is a factor that can limit its adoption, and can restrain market growth to a certain extent over the forecast period.
Product Type Outlook:
On the basis of product type, the deep brain stimulation devices market has been segmented into single-channel deep brain stimulator and dual-channel deep brain stimulator. Dual- channel deep brain stimulator segment accounted for largest revenue share in 2020. Rising adoption of dual-channel based deep brain stimulators in surgical procedures for its efficacy and safety features is expected to drive growth of this segment. Dual-channel neurostimulator devices enables bilateral therapy by delivering stimulation to two separate deep brain stimulation leads, which deliver controlled electric pulses to targeted areas of the brain in a precise manner. Increased use of dual channel deep brain stimulation devices in hospitals to treat Parkinson’s Disease, dystonia, essential tumors, and OCDs is expected to drive revenue growth of this segment.
On the basis of application, the deep brain stimulation devices market has been segmented into Parkinson’s Disease (PD), epilepsy, essential tumor, Obsessive Compulsory Disorder (OCD), dystonia, and others. Parkinson’s disease segment is expected to account for largest revenue share over the forecast period owing to rising use of DBS devices to reduce and control the symptoms associated with PD. Deep brain stimulation is clinically approved for treating PD as it effectively eases tremors and stiffness usually experienced by PD patients. Increasing adoption of deep brain stimulation devices for significantly improving motor symptoms and quality of life of patients suffering with Parkinson’s Diseases is driving growth of this segment.
Epilepsy segment revenue is expected to expand at a robust CAGR over the forecast period owing to rising number of individuals suffering from epilepsy and increasing application of DBS in controlling seizures. According to World Health Organization, about 50 million people are estimated to live with epilepsy across the world. Growing prevalence of epilepsy is thereby providing opportunities to neurosurgeons to apply deep brain stimulation procedure in the treatment of epilepsy. A number of clinical trials has found that deep brain stimulation significantly reduce the frequency and severity of seizures caused by epilepsy and help people lead a better life.
On the basis of end-use, the deep brain stimulation devices market has been segmented into hospitals, Ambulatory Surgical Centers (ASCs), neurological clinics, and academic and research institutes. Hospitals segment is expected to account for largest revenue share in the global market owing to growing number of deep brain stimulation procedures performed in hospitals. In addition, hospitals implement technologically advanced deep brain stimulation devices to treat Parkinson’s Diseases, essential tumor, and epilepsy safely and accurately to prevent any surgical side effects on patients. In recent years, hospitals have been increasingly implementing advanced electrode technology for safely stimulating the target tissue. This is expected to boost revenue growth of this segment going ahead.
Ambulatory surgical centers segment revenue is expected to expand at a significantly rapid CAGR over the forecast period due to steady increase in the number of ambulatory surgical centers, rising adoption of deep brain stimulation devices to treat neurological diseases, and improving healthcare infrastructure in developed and developing countries. In addition, higher preference for treatment at ambulatory surgical centers owing to better healthcare services, low infection rates in comparison to hospitals, and affordable healthcare services is expected to boost revenue growth of this segment.
Based on regional analysis, North America is expected to account for largest revenue share in the global market, attributed to increasing number of clinical studies and clinical trials related to DBS and rising number of U.S Food and Drug Administration (FDA) approvals for testing efficacy of the procedure in a number of clinical applications. In addition, increasing investment to develop technologically advanced electrodes and deep brain stimulation devices by major players in the region is expected to drive market revenue growth. Increasing new product development and speedy product approvals in the region is also expected to boost growth of the North America market. For instance, U.S Food and Drug Administration (FDA) recently approved NeuroSphere Virtual Clinics, which is a connected care management platform launched by Abbott Laboratories. Patients having deep brain stimulation devices implanted can have their devices reprogrammed remotely without the need of visiting a specialist. Furthermore, availability of skilled neurosurgeons and well-established healthcare infrastructure in countries in the region is expected to continue to drive North America market growth.
Asia Pacific is expected to register robust revenue CAGR over the forecast period owing to rising prevalence of neurological disorders such as Parkinson’s Disease and epilepsy, and rising awareness regarding availability and benefits of various treatment options for neurological diseases, including deep brain stimulation. In addition, increasing government support for facilitating and conducting clinical trials on DBS for other neurological applications and procedures is expected to continue to boost revenue growth of the market.
The global deep brain stimulation devices market is fairly fragmented with a number of key players operating on global and regional levels. Key players are engaged in product development and strategic alliances to expand their respective product portfolio and gain a robust footing in the global market. Major players in the market include Boston Scientific Corporation, Abbott Laboratories, Medtronic PLC, Neuronetics Inc., Beijing PINS Medical Co., Ltd., NeuroPace Inc., Functional Neuromodulation Ltd., Nevro Corporation, LinaNova PLC, and NeuroOne Medical Technologies Corp.
Some Key Developments in the Market:
- In June 2020, Medtronic PLC announced the upgraded version of its deep brain stimulation system — Percept PC Neurostimulator – with Brainsense technology to reduce the symptoms associated with Parkinson’s Disease. The new technology not only delivers electrical impulses or electrical stimulation to the brain, but also captures the electrical activity of the bran, thereby significantly improving clinical outcome.
Segments Covered in the Report:
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of the market trends in each segment and sub-segment from 2022 to 2030. For this study, has segmented the deep brain stimulation devices market based on product type, application, end-use, and region:
Deep Brain Stimulation Devices Market Report Scope
Segments covered By Product Type Outlook, Application Outlook, End-Use Outlook, Regional Outlook
By Product Type Outlook
Single-Channel Deep Brain Stimulator
Dual-Channel Deep Brain Stimulator
By Application Outlook
Parkinson’s Disease (PD)
Obsessive Compulsory Disorder (OCD)
By End-Use Outlook
Ambulatory Surgical Centers (ASCs)
Academic and Research Institutes
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119140/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: